Qiagen N.V. Press Releases https://corporate.qiagen.com/generated by Q4Sun, 27 Sep 2026 10:26:36 -0400Copyright Q4 Inc. All rights reserved.QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation368ec556-063a-4ce8-bc7f-77e0ece202dahttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Launches-QIAmini-to-Automate-Small-Batch-Sample-Preparation/default.aspxThu, 24 Sep 2026 16:05:00 -0400QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Boardc8e76cd0-b73a-4354-8bf4-84bfe9578aefhttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Calls-Extraordinary-General-Meeting-for-Appointment-of-Jonathan-M--Pratt-to-Managing-Board/default.aspxFri, 18 Sep 2026 16:05:00 -0400QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extractionf28d1496-c7df-4ee0-932a-f7ed1cab8419https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Launches-QIAsymphony-Connect-for-Automated-Clinical-Nucleic-Acid-Extraction/default.aspxThu, 27 Aug 2026 16:05:00 -0400QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer3e940fca-8726-4738-84c7-68e300f5248ahttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Appoints-Jonathan-M--Pratt-as-Chief-Executive-Officer/default.aspxMon, 24 Aug 2026 09:47:00 -0400QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel8e627d5f-335a-4d27-9611-7471d970c163https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Receives-U-S--FDA-Clearance-for-First-QIAstat-Dx-Bloodstream-Infection-Panel/default.aspxMon, 10 Aug 2026 16:05:00 -0400QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook21bb4d04-8f85-494a-95c4-3580989dbe10https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Exceeds-Q2-2026-Outlook-as-Pillars-Deliver-Solid-Sales-Growth-Reaffirms-Full-Year-Outlook/default.aspxWed, 05 Aug 2026 16:05:00 -0400QIAGEN highlights molecular testing solutions supporting response to growing U.S. Cyclospora outbreak065d7ac7-d61b-47ab-8347-54fad066845fhttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Highlights-Molecular-Testing-Solutions-Supporting-Response-to-Growing-U-S--Cyclospora-Outbreak/default.aspxWed, 15 Jul 2026 16:05:00 -0400QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast794a9876-e7de-4c21-a942-5e0ed81a9087https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-N-V--to-Release-Results-for-Q2-2026-and-Hold-Webcast/default.aspxWed, 15 Jul 2026 08:48:00 -0400QIAGEN expands QIAstat-Dx bloodstream infection testing menu in Europed411c5c5-b27c-4232-8773-12e95dc750c1https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Expands-QIAstat-Dx-Bloodstream-Infection-Testing-Menu-in-Europe/default.aspxTue, 14 Jul 2026 16:05:00 -0400QIAGEN announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 202720028a37-d41b-4aa7-a37d-cbcf6ccd69a1https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-announces-adjustment-of-conversion-price-under-its-US500000000-Convertible-Bonds-due-2027/default.aspxTue, 07 Jul 2026 18:00:00 -0400